BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1537 related articles for article (PubMed ID: 31900358)

  • 1. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy.
    Earls RH; Menees KB; Chung J; Gutekunst CA; Lee HJ; Hazim MG; Rada B; Wood LB; Lee JK
    Proc Natl Acad Sci U S A; 2020 Jan; 117(3):1762-1771. PubMed ID: 31900358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's disease.
    Reyes JF; Ekmark-Léwen S; Perdiki M; Klingstedt T; Hoffmann A; Wiechec E; Nilsson P; Nilsson KPR; Alafuzoff I; Ingelsson M; Hallbeck M
    Acta Neuropathol Commun; 2021 Mar; 9(1):46. PubMed ID: 33743820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro models of synucleinopathies: informing on molecular mechanisms and protective strategies.
    Marvian AT; Koss DJ; Aliakbari F; Morshedi D; Outeiro TF
    J Neurochem; 2019 Sep; 150(5):535-565. PubMed ID: 31004503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.
    Schaser AJ; Stackhouse TL; Weston LJ; Kerstein PC; Osterberg VR; López CS; Dickson DW; Luk KC; Meshul CK; Woltjer RL; Unni VK
    Acta Neuropathol Commun; 2020 Aug; 8(1):150. PubMed ID: 32859276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligodendrocytes Prune Axons Containing α-Synuclein Aggregates In Vivo: Lewy Neurites as Precursors of Glial Cytoplasmic Inclusions in Multiple System Atrophy?
    De Nuccio F; Kashyrina M; Serinelli F; Laferrière F; Lofrumento DD; De Giorgi F; Ichas F
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
    Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insights and Implications of Natural Killer Cells in Parkinson's Disease.
    Menees KB; Lee JK
    J Parkinsons Dis; 2022; 12(s1):S83-S92. PubMed ID: 35570499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
    Miraglia F; Betti L; Palego L; Giannaccini G
    Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of One Engrailed1 Allele Enhances Induced α-Synucleinopathy.
    Chatterjee D; Sanchez DS; Quansah E; Rey NL; George S; Becker K; Madaj Z; Steiner JA; Ma J; Escobar Galvis ML; Kordower JH; Brundin P
    J Parkinsons Dis; 2019; 9(2):315-326. PubMed ID: 30932894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Slow Progressive Accumulation of Oligodendroglial Alpha-Synuclein (α-Syn) Pathology in Synthetic α-Syn Fibril-Induced Mouse Models of Synucleinopathy.
    Uemura N; Uemura MT; Lo A; Bassil F; Zhang B; Luk KC; Lee VM; Takahashi R; Trojanowski JQ
    J Neuropathol Exp Neurol; 2019 Oct; 78(10):877-890. PubMed ID: 31504665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Detection of Alpha-Synuclein Seeding Activity in the Colon of a Transgenic Mouse Model of Synucleinopathy by RT-QuIC.
    Han JY; Shin C; Choi YP
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33926043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GV-971 attenuates α-Synuclein aggregation and related pathology.
    Yu Z; Yang Y; Chan RB; Shi M; Stewart T; Huang Y; Liu Z; Lan G; Sheng L; Tian C; Yang D; Zhang J
    CNS Neurosci Ther; 2024 Feb; 30(2):e14393. PubMed ID: 37563872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery.
    Arotcarena ML; Teil M; Dehay B
    Cells; 2019 Jun; 8(6):. PubMed ID: 31181865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
    Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
    Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 77.